Top Medical News
Tristan Manalac, 3 days ago
Chronic hepatitis C patients with sustained virological response (SVR) after treatment may still be at risk of hepatocellular carcinoma (HCC), a new study reports. Risk factors include a lower platelet count, cirrhosis and elevated aspartate aminotransferase (AST) levels.
Saras Ramiya, 5 days ago

The Asia Pacific Viral Hepatitis Policy Survey of 13 Asian countries and territories identifies gaps in health systems for hepatitis elimination.

7 days ago
Serum concentrations of angiopoietin-like 8 (ANGPTL8) are lower in patients with Prader-Willi Syndrome (PWS) and may predict liver steatosis severity, a new study shows.
Pearl Toh, 10 days ago
Both structured lifestyle intervention and liraglutide treatment induced significant weight loss in obese, nondiabetic Asian patients with nonalcoholic fatty liver disease (NAFLD), according to a pilot randomized trial.
Pearl Toh, 15 days ago
Larotrectinib delivers durable response across diverse cancer types, including paediatric and adult cancers, according to an interim analysis of three ongoing trials presented at the ASCO 2017 Annual Meeting.
Roshini Claire Anthony, 16 days ago

Selective internal radiation therapy (SIRT) did not fare better than sorafenib in terms of overall survival (OS) in patients with locally advanced hepatocellular carcinoma (HCC), though it appeared to be associated with fewer total adverse events, according to findings of the phase III, multicentre (11 Asia-Pacific countries), open-label SIRveNIB* study.

Pearl Toh, 17 days ago
Treatment with capecitabine after surgery for biliary tract cancer improves overall survival (OS) by 15 months compared with observation after surgery, according to the BILCAP* study presented at the ASCO 2017 Annual Meeting in Chicago, Illinois, US.
Special Reports
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
09 Nov 2016
At a recent Abbott-sponsored satellite symposium held during the GUT Congress 2016 in Kuala Lumpur, an expert from India presented on the management of alcoholic liver disease, and illustrated the role of SAMe as a complementary therapy.
26 Sep 2016
In this edition of MIMS Hepatology, we bring you recent updates in the treatment of hepatitis C, as well as highlights from two lectures presented in conjunction with the launch of Harvoni® (ledipasvir/sofosbuvir; LF Asia). 
30 Oct 2015
VIEKIRA PAK– ombitasvir, paritaprevir, ritonavir 12.5/7.5/50 mg tab copackaged with dasabuvir 250 mg film-coated tab,an innovative treatment for genotype 1 chronic hepatitis C.
03 Sep 2015
At a recent Abbott-sponsored symposium during the 11th Liver Update 2015, Professor José Mato discussed the role of S-adenosylmethionine (SAMe) in liver diseases. The following are highlights from his talk.
03 Sep 2015
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors. 
Conference Reports
Pearl Toh, 09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

Pearl Toh, 08 Mar 2017
Add-on of pegylated interferon (pegIFN) to nucleos(t)ide analogues (NA) therapy may be a better strategy than a switch from NA to pegIFN in patients with chronic hepatitis B (CHB) who are on long-term NA therapy, according to data from an interim analysis of the SWAP* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.
Tristan Manalac, 25 Feb 2017
Compared with viral hepatocellular carcinomas and those of other aetiologies, cryptogenic hepatocellular carcinomas tend to manifest at later stages and are associated with worse survival, according to a study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017).
Pearl Toh, 24 Feb 2017
The goal of treatment for portal hypertension varies depending on the different stages and substages of cirrhosis, and hence, pharmacological therapies for managing portal hypertension should be considered in the context of other complications of cirrhosis, according to a presentation at the recent APASL 2017 held in Shanghai, China recently.
24 Feb 2017
Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.
Roshini Claire Anthony, 23 Feb 2017

The use of statins is associated with a lower risk of pyogenic liver abscess, according to a Taiwan population-based case-control study. 

Elaine Soliven, 23 Feb 2017

Statin therapy may reduce the risk of cirrhosis and its associated comorbidities in chronic hepatitis B (CHB) patients, according to a presentation at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2017 held in Shanghai, China.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD